Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

1356960

USP

Leflunomid

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

5-Methylisoxazol-4-(4-trifluormethyl)-carboxanilid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C12H9F3N2O2
CAS-Nummer:
75706-12-6
Molekulargewicht:
270.21
MDL-Nummer:
MFCD00867593
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329750235
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

leflunomide

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F

InChI

1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)

InChIKey

VHOGYURTWQBHIL-UHFFFAOYSA-N

Angaben zum Gen

human ... DHODH(1723)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Leflunomide is a drug with cytotoxic properties. It is generally used as an immunosuppressive agent.

Anwendung

Leflunomide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Y0000654

Leflunomid, European Pharmacopoeia (EP) Reference Standard

Y0000674

Leflunomid für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard

Y0000487

Leflunomid Unreinheit A, European Pharmacopoeia (EP) Reference Standard

1357045

Leflunomid-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1357056

Leflunomid-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

1357067

Leflunomid-verwandte Verbindung C, United States Pharmacopeia (USP) Reference Standard

PHR1568

Leflunomid-verwandte Verbindung A, Pharmaceutical Secondary Standard; Certified Reference Material

BP1233

Leflunomid, British Pharmacopoeia (BP) Reference Standard

PHR2878

Leflunomid-verwandte Verbindung B, pharmaceutical secondary standard, certified reference material

Piktogramme

Skull and crossbones
GHS06

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 3

1 of 3

Teriflunomid ≥98% (HPLC)

Sigma-Aldrich

SML0936

Teriflunomid

Cephapirin Natrium United States Pharmacopeia (USP) Reference Standard

USP

1102500

Cephapirin Natrium

4-(Trifluormethyl)-anilin 99%

Sigma-Aldrich

224936

4-(Trifluormethyl)-anilin

S Greene et al.
Biochemical pharmacology, 50(6), 861-867 (1995-09-07)
Leflunomide [HWA 486 or RS-34821, 5-methyl-N-(4-trifluoromethylphenyl)-4-isoxazole carboximide] is an immunosuppressive agent effective in the treatment of rheumatoid arthritis. In spite of its clinical potential, its mechanism of action has not been elucidated. Recent studies suggest that leflunomide may interfere with
Robert P Baughman et al.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 21(1), 43-48 (2004-05-07)
Leflunomide (Arava) is a cytotoxic drug which has been used as a single agent or in combination with methotrexate for the treatment of rheumatoid arthritis. It appears to have less toxicity than methotrexate. The use of leflunomide for sarcoidosis patients
Young H Jung et al.
Pediatric transplantation, 17(2), E50-E54 (2012-12-06)
The BK virus (BKV) can be reactivated with immunosuppressive treatment in renal allograft recipients, which can result in interstitial nephritis (BKV-associated nephropathy, BKVAN) and lead to renal allograft failure. Recently, leflunomide has been reported in some case series of BKVAN
Helen I Keen et al.
Expert opinion on drug safety, 12(4), 581-588 (2013-05-15)
Leflunomide is a prodrug which is rapidly converted following oral administration and absorption to an active metabolite with anti-proliferative effects (A77 1726/teriflunomide). Leflunomide was developed as an immunomodulatory agent and subsequently developed as a disease-modifying anti-rheumatic drug (DMARD) for the
Shymaa E Bilasy et al.
Pharmacological reports : PR, 67(1), 102-114 (2015-01-07)
Safety of the combination of leflunomide and methotrexate was examined in several studies with inconclusive results. The present study was designed to compare the efficacy and safety of the combination of leflunomide and methotrexate in adjuvant-induced arthritis (AIA) in rats
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.